

✓
Please amend the claims as follows:

C2 ✓-12. (Amended) A cross-linked hyaluronic acid according to Claim 17 wherein the hydroxy groups are sulphated or hemi-succinylated. ✓-

✓-14. (Amended) A metal complex of a cross linked hyaluronic acid according to Claim 17 in which the metal is selected from zinc, copper or iron. ✓-

C3 ✓-15. (Amended) A pharmaceutical composition useful as (a) a substitute for synovial fluid in the treatment of osteo-arthritic conditions and for vitreous humor in the treatment of pathologies and side effects connected to ophthalmic surgery; (b) as a base for artificial tears formulation; (c) as a controlled release matrix of a medicament; and (d) as a healing and anti-adhesive agent, in which the principal active ingredient is a cross-linked hyaluronic acid according to Claim 17. ✓-

Please cancel Claims 1-4, 13 and 16.

REMARKS

A reconsideration of this application is respectfully requested. New Claim 17 is presented in independent form to clearly define the preferred embodiment of the invention. It has further been drafted in a manner to address the Section 112, para. 2 objection set forth in Paras. 2 and 3 of the Office Action. Claims 12, 14 and 15 have been amended so as to be dependent from new Claim 17 while Claims 1-4, 13 and 16 have been cancelled. It is submitted that the claims remaining of record are free of